Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells

Cao,Wei‑Jie; Wu,Ke; Wang,Chong; Wan,Ding‑Ming

doi:10.3892/mmr.2016.4909

Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells

Authors:
- Wei‑Jie Cao
- Ke Wu
- Chong Wang
- Ding‑Ming Wan
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Endodontics, The Fourth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: February 18, 2016 https://doi.org/10.3892/mmr.2016.4909
Pages: 3297-3302

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polydatin (PD), a natural precursor of resveratrol, has a variety of biological activities, including anti‑tumor effects. However, the underlying molecular mechanisms of the anti-cancer activity of PD has not been fully elucidated. The present study demonstrated that PD significantly inhibited the proliferation of the MOLT-4 leukemia cell line in a dose‑ and time-dependent manner by using Cell Counting Kit‑8 assay. PD also dose-dependently increased the apoptotic rate and caused cell cycle arrest in S phase in MOLT‑4 cells, as revealed by flow cytometry. In addition, PD dose-dependently decreased the mitochondrial membrane potential and led to the generation of reactive oxygen species in MOLT-4 cells. Western blot analysis revealed that the expression of anti‑apoptotic protein B-cell lymphoma 2 (Bcl-2) was decreased, whereas that of pro‑apoptotic protein Bcl‑2‑associated X was increased by PD. Furthermore, the expression of two cell cycle regulatory proteins, cyclin D1 and cyclin B1, was suppressed by PD. Of note, the pro‑apoptotic and cell cycle‑inhibitory effects of PD were potentiated by Janus kinase 2 (JAK2) inhibition. In conclusion, the results of the present study strongly suggested that PD is a promising therapeutic compound for the treatment of leukemia, particularly in combination with JAK inhibitors.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gregers J, Gréen H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B, Schmiegelow K and Peterson C: Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 15:372–379. 2015. View Article : Google Scholar : PubMed/NCBI
3	Neumann M, Vosberg S, Schlee C, Heesch S, Schwartz S, Gökbuget N, Hoelzer D, Graf A, Krebs S, Bartram I, et al: Mutational spectrum of adult T-ALL. Oncotarget. 6:2754–2766. 2015. View Article : Google Scholar : PubMed/NCBI
4	Pui CH and Evans WE: Acute lymphoblastic leukemia. N Engl J Med. 339:605–615. 1998. View Article : Google Scholar : PubMed/NCBI
5	Mehta RG and Pezzuto JM: Discovery of cancer preventive agents from natural products: From plants to prevention. Curr Oncol Rep. 4:478–486. 2002. View Article : Google Scholar : PubMed/NCBI
6	Du QH, Peng C and Zhang H: Polydatin: A review of pharmacology and pharmacokinetics. Pharm Biol. 51:1347–1354. 2013. View Article : Google Scholar : PubMed/NCBI
7	Zhang Q, Tan Y, Zhang N and Yao F: Polydatin prevents angiotensin II-induced cardiac hypertrophy and myocardial superoxide generation. Exp Biol Med (Maywood). 2014. View Article : Google Scholar
8	Dong M, Ding W, Liao Y, Liu Y, Yan D, Zhang Y, Wang R, Zheng N, Liu S and Liu J: Polydatin prevents hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes and pressure-overload mouse models. Eur J Pharmacol. 746:186–197. 2015. View Article : Google Scholar
9	Ding W, Dong M, Deng J, Yan D, Liu Y, Xu T and Liu J: Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway. Am J Physiol Heart Circ Physiol. 307:H792–H802. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhang Q, Tan Y, Zhang N and Yao F: Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats. Mol Med Rep. 11:603–610. 2015.
11	Sun J, Qu Y, He H, Fan X, Qin Y, Mao W and Xu L: Protective effect of polydatin on learning and memory impairments in neonatal rats with hypoxic-ischemic brain injury by up-regulating brain-derived neurotrophic factor. Mol Med Rep. 10:3047–3051. 2014.PubMed/NCBI
12	Ravagnan G, De Filippis A, Cartenì M, De Maria S, Cozza V, Petrazzuolo M, Tufano MA and Donnarumma G: Polydatin, a natural precursor of resveratrol, induces β-defensin production and reduces inflammatory response. Inflammation. 36:26–34. 2013. View Article : Google Scholar
13	De Maria S, Scognamiglio I, Lombardi A, Amodio N, Caraglia M, Cartenì M, Ravagnan G and Stiuso P: Polydatin, a natural precursor of resveratrol, induces cell cycle arrest and differentiation of human colorectal Caco-2 cell. J Transl Med. 11:2642013. View Article : Google Scholar : PubMed/NCBI
14	Zhang Y, Zhuang Z, Meng Q, Jiao Y, Xu J and Fan S: Polydatin inhibits growth of lung cancer cells by inducing apoptosis and causing cell cycle arrest. Oncol Lett. 7:295–301. 2014.
15	Liu H, Zhao S, Zhang Y, Wu J, Peng H, Fan J and Liao J: Reactive oxygen species-mediated endoplasmic reticulum stress and mitochondrial dysfunction contribute to polydatin-induced apoptosis in human nasopharyngeal carcinoma CNE cells. J Cell Biochem. 112:3695–3703. 2011. View Article : Google Scholar : PubMed/NCBI
16	Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BK, Matsuoka M, Yamaguchi K, Takatsuki K, Kamihira S, White JD, et al: Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proc Natl Acad Sci USA. 94:13897–13902. 1997. View Article : Google Scholar
17	Alas S and Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 61:5137–5144. 2001.PubMed/NCBI
18	Wu EY, Smith MT, Bellomo G and Di Monte D: Relationships between the mitochondrial transmembrane potential, ATP concentration and cytotoxicity in isolated rat hepatocytes. Arch Biochem Biophys. 282:358–362. 1990. View Article : Google Scholar : PubMed/NCBI
19	Medjkane S, Perichon M, Marsolier J, Dairou J and Weitzman JB: Theileria induces oxidative stress and HIF1 α activation that are essential for host leukocyte transformation. Oncogene. 33:1809–1817. 2014. View Article : Google Scholar
20	Wang C and Youle RJ: The role of mitochondria in apoptosis. Annu Rev Genet. 43:95–118. 2009. View Article : Google Scholar
21	Gottlieb E, Armour SM, Harris MH and Thompson CB: Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 10:709–717. 2003. View Article : Google Scholar : PubMed/NCBI
22	Herrera B, Alvarez AM, Sánchez A, Fernández M, Roncero C, Benito M and Fabregat I: Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor (beta) in fetal hepatocytes. FASEB J. 15:741–751. 2001. View Article : Google Scholar : PubMed/NCBI
23	Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, et al: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 379:645–648. 1996. View Article : Google Scholar : PubMed/NCBI
24	Xu JY, Meng QH, Chong Y, Jiao Y, Zhao L, Rosen EM and Fan S: Sanguinarine inhibits growth of human cervical cancer cells through the induction of apoptosis. Oncol Rep. 28:2264–2270. 2012.PubMed/NCBI
25	Singh CK, Ndiaye MA and Ahmad N: Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta. 1852:1178–1185. 2015. View Article : Google Scholar
26	Francioso A, Mastromarino P, Masci A, d'Erme M and Mosca L: Chemistry, stability and bioavailability of resveratrol. Med Chem. 10:237–245. 2014. View Article : Google Scholar
27	Krasnow MN and Murphy TM: Polyphenol glucosylating activity in cell suspensions of grape (Vitis vinifera). J Agric Food Chem. 52:3467–3472. 2004. View Article : Google Scholar : PubMed/NCBI
28	Daniel PT, Koert U and Schuppan J: Apoptolidin: Induction of apoptosis by a natural product. Angew Chem Int Ed Engl. 45:872–893. 2006. View Article : Google Scholar : PubMed/NCBI
29	Circu ML and Aw TY: Glutathione and modulation of cell apoptosis. Biochim Biophys Acta. 1823:1767–1777. 2012. View Article : Google Scholar : PubMed/NCBI
30	Ghobrial IM, Witzig TE and Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
31	Qu K, Shen NY, Xu XS, Su HB, Wei JC, Tai MH, Meng FD, Zhou L, Zhang YL and Liu C: Emodin induces human T cell apoptosis in vitro by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction. Acta Pharmacol Sin. 34:1217–1228. 2013. View Article : Google Scholar : PubMed/NCBI
32	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
33	Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 11:558–572. 2011. View Article : Google Scholar : PubMed/NCBI
34	Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H and Sicinski P: The requirement for cyclin D function in tumor maintenance. Cancer Cell. 22:438–451. 2012. View Article : Google Scholar : PubMed/NCBI
35	Yang K, Hitomi M and Stacey DW: Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div. 1:322006. View Article : Google Scholar : PubMed/NCBI
36	Vainchenker W and Constantinescu SN: JAK/STAT signaling in hematological malignancies. Oncogene. 32:2601–2613. 2013. View Article : Google Scholar
37	James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, et al: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 434:1144–1148. 2005. View Article : Google Scholar : PubMed/NCBI
38	Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387–397. 2005. View Article : Google Scholar : PubMed/NCBI
39	Lu M, Wang J, Li Y, Berenzon D, Wang X, Mascarenhas J, Xu M and Hoffman R: Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 116:4284–4287. 2010. View Article : Google Scholar : PubMed/NCBI